SHR 117887

Drug Profile

SHR 117887

Alternative Names: SHR-117887

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 24 Feb 2016 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus (Combination therapy) in China (PO)
  • 30 Jun 2012 Phase-II clinical trials in Type-2 diabetes mellitus in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top